about
Non-SH2/PDZ reverse signaling by ephrinsMutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancerDiscovery and characterization of a novel cyclic peptide that effectively inhibits ephrin binding to the EphA4 receptor and displays anti-angiogenesis activityThe phosphorylation of ephrin-B2 ligand promotes glioma cell migration and invasion.Eph receptors and ephrins in cancer: bidirectional signalling and beyond.EphrinB1 interacts with CNK1 and promotes cell migration through c-Jun N-terminal kinase (JNK) activationEphrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survivalEph/ephrin interactions modulate muscle satellite cell motility and patterning.EphA2 Is a Potential Player of Malignant Cellular Behavior in Non-Metastatic Renal Cell Carcinoma Cells but Not in Metastatic Renal Cell Carcinoma Cells.Irradiation affects cellular properties and Eph receptor expression in human melanoma cells.Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinomaInvestigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer.Loss of the EPH receptor B6 contributes to colorectal cancer metastasisA review on Eph/ephrin, angiogenesis and lymphangiogenesis in gastric, colorectal and pancreatic cancersCancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms.Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine.C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.
P2860
Q24629619-B7647C63-0EF0-47F8-B538-3CA504371154Q30528942-3EE17A43-959E-4341-B232-9B216742D1DAQ31144324-6038EB83-4512-4042-919D-5647BF37CC1BQ33499806-392C3EA2-9F4F-4724-9E12-B1F81F387F4FQ34021365-25F81AF4-F612-476D-974E-BB5AE25997BAQ34073875-8C861291-EF7F-4490-BB20-FB34FB491C06Q34524860-2847278E-859A-4995-89D5-A89859BAFC34Q35567787-C6EBAAF9-1351-41FC-A6B1-541ACE3C857CQ35692688-F0B22D37-5C6A-4EC0-B414-190D880FA8D2Q36402715-74377D70-C653-4939-B08E-B70A31A4A4C5Q37432375-82904977-98C8-4426-8319-AB46181AE052Q37627879-E346DA16-E903-4A99-A38B-6F83A3B0B965Q37681807-16D49354-EDB7-4EF6-820D-EBC437BFA370Q41662329-4EB1FB7E-A414-40EF-9FE7-EB79F06C6E51Q41782765-03BD7267-7840-4245-9D79-273C7D5C2DF4Q41954025-74F1FD03-E3D6-405D-84D6-C085A80AD65FQ46591244-8A74B9C6-4144-4B00-8C76-70C5A287107C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
EPH receptors in cancer.
@en
EPH receptors in cancer.
@nl
type
label
EPH receptors in cancer.
@en
EPH receptors in cancer.
@nl
prefLabel
EPH receptors in cancer.
@en
EPH receptors in cancer.
@nl
P50
P356
P1476
EPH receptors in cancer
@en
P2093
Julio Castaño
P304
P356
10.14670/HH-23.1011
P577
2008-08-01T00:00:00Z